Objectives: Macrolide therapy is an important conservative therapy for chronic rhinosinusitis, especially in Japan. The mechanism underlying this therapy involves anti-inflammatory and not antimicrobial activity. However, the administration of long-term low-dose macrolides (LTLMs) causes an increase in the number of antibiotic-resistant bacteria. EM900 is a derivative of erythromycin (EM), with antiinflammatory but not antibacterial effects. It does not induce macrolide-resistant bacteria as shown by LTLM. In the present study, we analyzed the inhibitory effects of EM900 in comparison with those of clarithromycin (CAM) on inflammatory cytokine production in human nasal epithelial cells (HNEpCs).
Introduction
Long-term administration of low-dose 14-membered ring macrolides, such as clarithromycin (CAM) and erythromycin (EM), has been shown to markedly improve diffuse panbronchiolitis 1 , chronic bronchitis 2, 3 , and chronic rhinosinusitis (CRS) 2, 4 . Therefore, long-term low-dose macrolide (LTLM) therapy is primarily chosen to treat representative chronic inflammatory diseases, such as CRS, in the field of rhinology. Although the mechanism underlying macrolide efficacy has been assumed to involve anti-inflammatory and not antimicrobial activity, the details regarding the exact mechanism remain unclear 5 .
LTLM has been shown to contribute to the increase in the number of antibiotic-resistant bacteria. Therefore, EM900 series were developed as the derivatives of EM; EM900 has been characterized by anti-inflammatory but not antimicrobial effects 6, 7 .
The formation of nasal polyps is a typical mucosal remodeling phenomenon, contributing to the refractory pathology of CRS. However, the details underlying the pathogenesis of polyps remain unclear. Although nasal polyps have been considered to result due to neutrophilic inflammation, the mechanism underlying the occurrence of refractory and recurrent nasal polyps in cases with eosinophilic sinusitis remains unclear. Interleukin (IL)-8 is one of the representative inflammatory cytokines produced by macrophages and neutrophils migrating into the paranasal sinus mucosa under the influence of viral or bacterial infection and microvillus components 8, 9 . Fur-thermore, vascular endothelial growth factor (VEGF) is produced by inflammatory epithelial cells and fibroblasts.
VEGF has two major pathological functions: angiogenesis and hypervascular permeability. The outgrowth of the sinus edematous mucosa due to VEGF is thought to be an important initial step in the formation of nasal polyps 10 .
According to studies using fibroblasts from nasal polyps, VEGF production increases under hypoxic conditions in paranasal sinuses 11 , particularly in cases with allergic rhinitis; a significant increase in VEGF production from nasal mucosal fibroblasts is regarded as an exacerbating factor for allergic CRS 12 . Hence, VEGF seems to play an important role in the pathogenesis of CRS.
Furthermore, tumor necrosis factor (TNF)-α levels in the remaining fluid increase in the paranasal sinuses of CRS cases 11 . Studies using cultured nasal polyp fibroblasts have shown that macrolides, such as CAM, inhibited the production of IL-8 and VEGF in the presence of TNF-α stimulation 8, 13 . Although nasal epithelial cells directly facing nasal and paranasal circumstances exhibit an important initial response in mucosal inflammation, it remains unclear whether macrolides including derivatives inhibit the epithelial inflammatory response monitored by cytokine production. In the present study, to elucidate the anti-inflammatory effect of EM900 compared with that of CAM, cultured human nasal epithelial cells (HNEpCs; Promo Cell, Germany) were stimulated with TNF-α, and the inhibitory effects on inflammatory cytokine production were compared between CAM and EM900.
Materials and Methods

Drugs
We used CAM powder, a conventional 14-membered ring macrolide antibiotic, provided by Taisho Toyama Pharmaceutical Co., Ltd. It was dissolved in dimethyl sulfoxide (DMSO) to obtain a concentration of 2,000 μg/ mL and diluted with sterile water and culture medium to 
IL-8 and VEGF
The levels of IL-8 and VEGF in the supernatant were measured using ELISA kits for human IL-8 and VEGF
(Life Technologies, MA, USA).
In cultured cells, mRNA expression was determined using RT-PCR. Commercial primers were used. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an intrinsic control.
Statistical Analysis
Wilcoxon's t-test was used for statistical analysis.
Ethical Statement
Because commercially available cultured cells were used in the present study, an application was not submitted to the Ethics Review Board.
Results
Effects of CAM and EM900 on IL-8 Production
Using both an ELISA and RT-PCR, we confirmed that TNF-α stimulation alone significantly enhanced the production of IL-8 ( Fig. 1 and 2 ; n=7). The TNF-α-stimulated cultured HNEpCs were treated with CAM or EM900, and their significant, dose-dependent inhibitory effects on IL-8 production were noted using both the ELISA and RT-PCR.
Effects of CAM and EM900 on VEGF production
Using both the ELISA and RT-PCR, we confirmed that TNF-α stimulation alone significantly enhanced the production of VEGF ( Fig. 3 and 4 ; n=7). Regarding the inhibitory effects of macrolides, the ELISA demonstrated that the addition of 10 −6 M EM900 significantly inhibited the production of VEGF. However, there were no significant changes with any other EM900 concentration. In Effects of clarithromycin (CAM) and EM900 (n=7). (A) Administration of EM900 and 10 ng/mL of tumor necrosis factor (TNF) -α. (B) Administration of CAM and 10 ng/mL of TNF-α. IL-8 mRNA expression was standardized with that of glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA as an internal control. RT-PCR confirmed that TNF-α stimulation alone significantly enhanced the production of IL-8. The TNF-α-stimulated cultured human nasal epithelial cells were treated with CAM or EM900. Their significant, dose-dependent inhibitory effects on IL-8 production were noted using RT-PCR. Mann-Whitney U-test; *P<0.05, **P<0.01. contrast, RT-PCR confirmed that there were no significant changes due to CAM or EM900 administration at any concentration.
Discussion
IL-8 and VEGF play important roles in the pathogenesis
of paranasal inflammation, and their effects can be suppressed by steroids 15 ; in the present study, the levels of and activator protein (AP)-1 4,8,9,16 19 . In the present study, we speculated that macrolides may inhibit IL-8 production enhanced by TNF-α stimulation. EM900 inhibited IL-8 production in a dose-dependent manner, as demonstrated by the administration of CAM. We suggested that EM900 as well as CAM, which is a clinically prevalent macrolide, inhibit neutrophil inflammation. According to another study, the concentration of CAM after oral administration of >150 mg was 4.50 μg/mL in the paranasal mucus 20 . In the present study, the maximum concentration of CAM was 10 −4 M (0.74 μg/mL) and that of EM900 was 10 −4 M (0.718 μg/mL); similar effects could also be obtained in vivo. Therefore, EM900 and CAM are equally effective against neutrophil-mediated CRS with respect to their tissue transferability.
In contrast, VEGF is a cytokine that promotes vascular endothelial proliferation and enhances vascular permeability, suggesting that VEGF-related outgrowth of the paranasal mucosa results in the formation of nasal polyps. Previous studies using cultured fibroblasts indicated that VEGF production is considerably enhanced in the presence of hypoxia or TNF-α stimulation 12, 13 . In the present study, TNF-α stimulation enhanced the production of VEGF in cultured HNEpCs. However, the inhibitory effects of CAM and EM900 on VEGF production were not consistently or significantly observed; the results of the inhibition experiment did not show a dose-dependent pattern between the changes in VEGF production and macrolides administered. The intracellular signalling pathway of TNF-α stimulation for VEGF production may be different between epithelial cells and mucosal fibroblasts. Therefore, the inhibitory effects of macrolides may have differed between these two cell types in the previous studies 13 . Further studies are necessary to elucidate the intracellular events related to VEGF production.
The new EM derivative EM900 significantly inhibited IL-8 production, similar to that observed using CAM administration. Therefore, EM900, which does not show antibiotic activity, can demonstrate promising antineutrophil inflammatory effects in CRS, similar to those observed using CAM.
Eosinophilic inflammatory CRS is increasing in Japan.
However, macrolides have no anti-eosinophil inflammatory effects. Therefore, according to previous reports, macrolides have no effect on eosinophilic inflammatory CRS. There is no experimental data or clinical data at the present time for the effect of EM900 on CRS. Therefore, further investigation is required on suppressive effects of EM900 on cytokines that cause eosinophilic inflammation.
The mucosal epithelium harvested during operations is repeatedly exposed to environmental pathogens and thus may be already stimulated. Therefore, the data may vary because of substances in the sinus fluid. The collection of normal human mucosal epithelium is ethically challenging. On the other hand, commercial nasal epithelial cells can be simply and constantly stimulated using TNF-α alone. Therefore, commercial cells were used in the present study to estimate the anti-inflammatory effects of EM900 compared with those of CAM.
Conclusion
The anti-inflammatory macrolide EM900 significantly inhibited IL-8 production in cultured HNEpCs. However, such an inhibitory effect was not observed on VEGF production, as observed in the experiment using fibroblasts.
EM900, as well as CAM, can be a promising drug for the treatment of neutrophil inflammation in CRS.
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